FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Gonsalves Daniel		 2. Date of Event Requiring Statement (MM/DD/YYYY)
10/6/2022 

 3. Issuer Name and Ticker or Trading Symbol

Bionik Laboratories Corp. [BNKL]
(Last)        (First)        (Middle)

C/O BIONIK LABORATORIES CORP., 80 COOLIDGE HILL ROAD		 4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                          _____ 10% Owner
___X___ Officer (give title below)        _____ Other (specify below)
Executive Vice President & CFO /
(Street)

WATERTOWN, MA 02472      

(City)              (State)              (Zip)
5. If Amendment, Date Original Filed(MM/DD/YYYY)
 

6. Individual or Joint/Group Filing(Check Applicable Line)

_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)		2. Amount of Securities Beneficially Owned
(Instr. 4)		3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)		4. Nature of Indirect Beneficial Ownership
(Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)		2. Date Exercisable and Expiration Date
(MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)		4. Conversion or Exercise Price of Derivative Security5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)		6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy) 10/14/2021 (1)10/14/2028 Common Stock 25000 $2.10 D  
Stock Option (Right to Buy) 10/6/2023 (2)10/6/2029 Common Stock 60000 $0.302 D  
Explanation of Responses:
(1) The option vests as to 6,250 underlying shares on the grant date of October 14, 2021, and each yearly anniversary thereafter. All 25,000 shares underlying the option will vest, subject to earlier termination in accordance with the terms of the option, on October 14, 2024.
(2) The option vests 1/3 on each of the first three anniversaries of the grant date of October 6, 2022. All 60,000 shares underlying the option will vest, subject to earlier termination in accordance with the terms of the option, on October 6, 2025.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Gonsalves Daniel
C/O BIONIK LABORATORIES CORP.
80 COOLIDGE HILL ROAD
WATERTOWN, MA 02472

Executive Vice President & CFO
Signatures
/s/ Daniel Gonsalves10/25/2022
**Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Bionik Laboratories (CE) (USOTC:BNKL)
Historical Stock Chart
From Nov 2024 to Dec 2024 Click Here for more Bionik Laboratories (CE) Charts.
Bionik Laboratories (CE) (USOTC:BNKL)
Historical Stock Chart
From Dec 2023 to Dec 2024 Click Here for more Bionik Laboratories (CE) Charts.